Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The Rockwell Medical (RMTI) news feed on Stock Titan focuses on company announcements that relate to its hemodialysis concentrates portfolio, supply agreements with dialysis providers, operational updates, and financial results.
Investors and healthcare observers following RMTI news can expect coverage of product purchase agreements with large dialysis providers, health systems, and specialized care organizations. Recent company communications describe multi-year contracts that include utilization or purchase minimums, options to renew, and supply of liquid and dry acid and bicarbonate concentrates, as well as Rockwell Medical’s dry acid concentrate mix system and bicarbonate cartridge. News items also highlight the company’s efforts to expand its customer base, including adding new dialysis customers in different regions of the United States.
The RMTI news stream also includes quarterly financial and operational results, typically released through earnings press releases and accompanied by conference call details. These updates discuss net sales, gross margin, adjusted EBITDA, and cash position, along with commentary on customer transitions, contract renewals, and manufacturing efficiency. In addition, Rockwell Medical issues news on leadership changes, such as board appointments and executive promotions, and on operational roles related to manufacturing and supply chain management.
Further topics in Rockwell Medical news include participation in industry events, such as exhibiting its hemodialysis concentrates portfolio at professional nephrology conferences, and recognition as a Great Place to Work® and a Fortune Best Workplaces in Manufacturing & Production™ honoree. For users tracking RMTI, this news page provides a centralized view of the company’s corporate developments, financial disclosures, and updates on its hemodialysis products and customer relationships.
Rockwell Medical, Inc. (Nasdaq: RMTI), a healthcare company specializing in hemodialysis products, has been recognized as one of the 2024 Fortune Best Workplaces in Manufacturing and Production in the small & medium category. This prestigious acknowledgment comes from Great Place to Work® and Fortune magazine.
Lesley Spriggs, Vice President of Human Resources at Rockwell Medical, expressed pride in the company's achievement, highlighting the dedication of their leadership and employees. The company's focus on manufacturing and delivering life-sustaining dialysis solutions for patients with end-stage kidney disease has been a key factor in this recognition.
Rockwell Medical (Nasdaq: RMTI) has announced a product purchase agreement with the leading at-home and acute care dialysis provider in the United States. The company will supply its RenalPure® liquid acid and SteriLyte® liquid bicarbonate hemodialysis concentrates to the customer. These products will be packaged in either four-per-case for larger dialysis settings or two-per-case for smaller acute care and at-home care settings.
Rockwell Medical's convenience pack, which includes two 1-gallon pre-mixed containers of either RenalPure or SteriLyte, offers advantages such as easier handling and streamlined workflow for home patients, caregivers, healthcare providers, and acute facilities. This agreement supports the customer's patient-centric care model and addresses the growing demand for technological advancements in the dialysis space, particularly in the underserved at-home hemodialysis segment.
Rockwell Medical (Nasdaq: RMTI) has entered into a multi-million dollar distribution agreement with Nipro Medical The agreement allows Nipro to distribute Rockwell's hemodialysis concentrates and mixer globally, excluding the United States. Key points:
- Two-year agreement with a one-year extension option
- Minimum product purchases of $5.0 million for the first year with incremental increases thereafter
- Covers liquid and dry acid concentrates, bicarbonate concentrates, and dry acid concentrates mixer
- Aims to meet increasing market demand for Rockwell's hemodialysis products
- Expands accessibility to Rockwell's products for dialysis patients worldwide
Rockwell Medical (RMTI) reported strong financial results for Q2 2024, achieving profitability on a cash flow and Adjusted EBITDA basis. Net sales increased 43% to $25.8 million, while gross profit surged 341% to $4.6 million. The company improved its gross margin to 18% from 6% in the same period last year. Notably, Rockwell generated $1.4 million in cash flow from operations.
The company raised its 2024 guidance, now expecting net sales between $95 million and $98 million. Rockwell projects mid-to-high single-digit growth in 2025 and beyond, with gross margins expected to reach above 25% by 2026. The positive results were driven by organic growth in hemodialysis concentrates products, streamlined production, and new customer contracts.
Rockwell Medical (Nasdaq: RMTI) has launched a Convenience Pack for its hemodialysis concentrate products CitraPure®, RenalPure®, and SteriLyte®. The pack includes two 1-gallon pre-mixed containers, offering easier handling and streamlined workflow for home hemodialysis patients, caregivers, and acute dialysis facilities.
This new packaging option aims to support the growing trend of at-home dialysis treatments, which can reduce costs and improve patient experience. Rockwell Medical provides FDA-regulated products, reliable delivery services, and adheres to ISO 13485 certification, cGMP, and AAMI standards. The company manufactures a full suite of hemodialysis products, including concentrates, powders, liquids, and accessories.
Rockwell Medical (Nasdaq: RMTI), a global healthcare company specializing in hemodialysis products, has announced its participation in the H.C. Wainwright 3rd Annual Kidney Virtual Conference. The company's President and CEO, Dr. Mark Strobeck, will be presenting at this virtual event.
Investors and interested parties can access the webcast of Rockwell Medical's presentation through the company's 'Investors' page at IR.RockwellMed.com. The webcast will remain available for 30 days following the conference. For more information about the conference, visit hcwevents.com/kidneyconference.
This presentation provides an opportunity for Rockwell Medical to showcase its portfolio of hemodialysis products and discuss its strategies in the kidney care market.
Rockwell Medical (Nasdaq: RMTI) announced it will release its financial and operational results for the second quarter of 2024 on August 8, 2024. The announcement will be made at 6:00am ET, followed by a live conference call and webcast at 8:00am ET. Rockwell Medical, a healthcare company specializing in hemodialysis products, will discuss the financial and operational results for the quarter ending June 30, 2024, and hold a Q&A session. The conference can be accessed via phone at (888) 660-6347 (domestic) or (929) 201-6594 (international) using Conference Call ID: 4944610, or via webcast at www.RockwellMed.com/Results.
Rockwell Medical (Nasdaq: RMTI) has promoted Tim Chole to the position of Chief Commercial Officer. Chole has been with the company since December 2019, initially serving as SVP of Sales and Marketing. In his new role, he will report to President and CEO Dr. Mark Strobeck. This promotion follows Rockwell's strategic shift in November 2022, aimed at enhancing revenue-generating businesses and driving profitability. Chole has over 20 years of experience in commercial roles within the pharmaceutical and medical device sectors, with a strong focus on renal care. Under his leadership, Rockwell has increased market share, improved gross margins, and achieved record net sales.
Rockwell Medical (Nasdaq: RMTI) reported record net sales of $22.7 million for Q1 2024, a 15% year-over-year increase. Gross profit rose 18% to $3.1 million, and gross margin improved to 14%. The net loss narrowed to $1.7 million, with adjusted EBITDA at ($0.5) million. The company raised its 2024 guidance, expecting net sales of $90-$94 million and gross profit of $13-$15 million. Rockwell Medical signed new distribution agreements and extended a loan maturity date, reducing interest rates. Cash reserves stood at $10.2 million at the end of Q1 2024.
Summary not available.